Emcure Pharmaceuticals Limited has made an Initial Public Offering of 19,375,070 equity shares amounting to ₹19,520.27 million (approximately USD 234 million). 

Shardul Amarchand Mangaldas & Co advised Emcure Pharma on this IPO.

The transaction team consisted of Nikhil Naredi (Partner), Priya Awasthi (Partner), Rakshita Poddar (Associate) and Manish Soni (Associate).

Khaitan & Co acted as the legal counsel to the Bankers i.e., Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited and J.P Morgan India Private Limited on this IPO.

The transaction team consisted of Chirayu Chandani (Partner), Aditya Cheriyan (Partner), Tishita Mukherjee (Senior Associate), Hrithik Khurana (Associate), Kaushlendra Palawat (Associate) and Shreya Iyer (Associate).

The Issue had an overall subscription of 68.50x, with the retail individual portion oversubscribed 7.49x; QIB portion oversubscribed 190.88x, non-institutional bidders (more than 0.20 million – up to 1.00 million) oversubscribed 39.05x and non-institutional bidders (above 1.00 million) oversubscribed 55.39x.

Emcure Pharmaceuticals Limited is a prominent pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. 

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.